STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Diamyd Medical (STO:DMYDY) announced today that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has posted a planned international clinical study with the Diamyd® GAD-alum diabetes vaccine in 126 new onset type 1 diabetes patients on the NIH clinical trials webpage, www.clinicaltrials.gov. The study is proposed by the NIH/NIDDK sponsored global network TrialNet, a group of the world’s foremost experts and key opinion leaders in type 1 diabetes.
